Author

R. C. Geck

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Toker· 2 shared A. R. Warwick· 1 shared B. Taylor· 1 shared E. B. Cohen· 1 shared J. M. Asara· 1 shared J. M. Boyer· 1 shared J. R. Foley· 1 shared K. Gunkelman· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Toker

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

yEvo: a modular eukaryotic genetics and evolution research experience for high school students

B. Taylor, A. R. Warwick, R. Skophammer, J. M. Boyer, R. C. Geck, K. Gunkelman, M. Walson, P. A. Rowley, M. J. Dunham

yEvo provides high school students with modular yeast evolution experiments to explore mutation, adaptation, and evolution through hands-on research.

bioRxiv · May 26, 2022Scientific Communication & Education

Metabolic pathway alterations in microvascular endothelial cells in response to hypoxia

E. B. Cohen, R. C. Geck, A. Toker

This study identifies metabolic pathway changes in microvascular endothelial cells under hypoxia, revealing potential targets for improving drug delivery and vessel normalization.

bioRxiv · Apr 8, 2020Cancer Biology

Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy

R. C. Geck, J. R. Foley, T. R. Murray Stewart, J. M. Asara, R. A. Casero, A. Toker

This study shows that inhibiting ODC with DFMO sensitizes TNBC cells to chemotherapy, but not receptor-positive breast cancer cells.

bioRxiv · Jan 8, 2020Cancer Biology